PURAPHARM CORPORATION LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.75 HKD | 0.00% |
|
0.00% | -16.67% |
| Apr. 01 | PuraPharm's Net Loss Shrinks in 2023; Revenue Falls 9% | MT |
| Mar. 28 | PuraPharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 741.4 | 515 | 334.2 | 267.2 | 319.1 | 505.7 |
| Enterprise Value (EV) 1 | 1,176 | 929.4 | 776.1 | 658.8 | 755 | 933 |
| P/E ratio | 384 x | 24.9 x | -1.47 x | 7.96 x | -2.62 x | -4.2 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 1.25 x | 0.69 x | 0.48 x | 0.44 x | 0.48 x | 1.13 x |
| EV / Revenue | 1.99 x | 1.25 x | 1.12 x | 1.09 x | 1.14 x | 2.08 x |
| EV / EBITDA | 44.7 x | 18 x | -25.8 x | 29.8 x | 18.8 x | -22.2 x |
| EV / FCF | -6.2 x | -234 x | 6.8 x | -24.6 x | -20.5 x | 14 x |
| FCF Yield | -16.1% | -0.43% | 14.7% | -4.07% | -4.87% | 7.16% |
| Price to Book | 1.35 x | 0.92 x | 0.92 x | 0.52 x | 0.79 x | 1.96 x |
| Nbr of stocks (in thousands) | 244,697 | 245,222 | 261,056 | 392,977 | 393,934 | 395,053 |
| Reference price 2 | 3.030 | 2.100 | 1.280 | 0.6800 | 0.8100 | 1.280 |
| Announcement Date | 4/23/18 | 4/9/19 | 4/16/20 | 4/21/21 | 4/26/22 | 4/26/23 |
1HKD in Million2HKD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 591.6 | 745.5 | 695.9 | 601.8 | 659.6 | 448.1 |
| EBITDA 1 | 26.3 | 51.57 | -30.1 | 22.11 | 40.12 | -42.11 |
| EBIT 1 | 1.518 | 15.98 | -61.59 | -1.253 | 15.14 | -68.25 |
| Operating Margin | 0.26% | 2.14% | -8.85% | -0.21% | 2.3% | -15.23% |
| Earnings before Tax (EBT) 1 | 10.33 | 26.53 | -216.2 | 40.22 | -117.2 | -119.2 |
| Net income 1 | 1.889 | 20.81 | -227.3 | 31.71 | -121.9 | -120.2 |
| Net margin | 0.32% | 2.79% | -32.66% | 5.27% | -18.48% | -26.83% |
| EPS 2 | 0.007899 | 0.0844 | -0.8716 | 0.0854 | -0.3095 | -0.3047 |
| Free Cash Flow 1 | -189.5 | -3.98 | 114.2 | -26.79 | -36.77 | 66.8 |
| FCF margin | -32.04% | -0.53% | 16.41% | -4.45% | -5.57% | 14.91% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/23/18 | 4/9/19 | 4/16/20 | 4/21/21 | 4/26/22 | 4/26/23 |
1HKD in Million2HKD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 434 | 414 | 442 | 392 | 436 | 427 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 16.52 x | 8.036 x | -14.68 x | 17.71 x | 10.87 x | -10.15 x |
| Free Cash Flow 1 | -190 | -3.98 | 114 | -26.8 | -36.8 | 66.8 |
| ROE (net income / shareholders' equity) | 0.38% | 3.74% | -49.2% | 7.26% | -26.7% | -36.4% |
| ROA (Net income/ Total Assets) | 0.09% | 0.76% | -3.01% | -0.06% | 0.73% | -3.84% |
| Assets 1 | 2,147 | 2,737 | 7,543 | -52,587 | -16,620 | 3,132 |
| Book Value Per Share 2 | 2.240 | 2.290 | 1.390 | 1.300 | 1.020 | 0.6500 |
| Cash Flow per Share 2 | 0.3500 | 0.4300 | 0.2600 | 0.2300 | 0.1500 | 0.1900 |
| Capex 1 | 102 | 45.2 | 66.4 | 76 | 3.09 | 20.8 |
| Capex / Sales | 17.18% | 6.06% | 9.55% | 12.64% | 0.47% | 4.65% |
| Announcement Date | 4/23/18 | 4/9/19 | 4/16/20 | 4/21/21 | 4/26/22 | 4/26/23 |
1HKD in Million2HKD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.67% | 37.85M | |
| +35.04% | 5.92B | |
| -15.13% | 4.51B | |
| -9.75% | 3.15B | |
| +2.14% | 3.1B | |
| -6.82% | 2.42B | |
| +47.87% | 1.97B | |
| -7.89% | 1.68B | |
| +0.09% | 1.65B | |
| -12.97% | 1.53B |
- Stock Market
- Equities
- 1498 Stock
- Financials PuraPharm Corporation Limited
